Vaxil Bio announces CEO David Goren to additional role of Chairman of the Board of Directors

– ISRAEL, Ness Ziona –  Vaxil Bio Ltd. (TSX: VXL), innovative immunotherapy biotech focused on cancer and infectious diseases, today announced that it has appointed David Goren, the Company’s CEO as its Chairman, replacing Isaac Maresky, who continues to serve on the board of directors.

Mr. Goren stated: “I am very excited about this appointment as the Company moves into this next exciting phase. We look forward to continuing to pursue our strategy of developing unique treatments that can make a meaningful difference to patients’ lives.”

He continued: “on behalf of the shareholders and the board of Vaxil, I thank Mr. Maresky for his role as chairman during the last year and a half.”

About Vaxil Bio Ltd.

Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin successfully completed a Phase 1/2 clinical trial in multiple myeloma and received orphan drug status from the FDA and EMA. The company continues to develop ImMucintm and is also developing a tuberculosis vaccine/treatment that has demonstrated promising preliminary results with further preclinical evaluation underway at a top US academic and research institution. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.

Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit, Vaxil’s proprietary bioinformatic approach. These SPs induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>